citiusonc.com (CTOR) - Company Sales

Corporate emblem and logo of Citius Oncology Inc. (CTOR)

Citius Oncology, Inc. (CTOR) bases its future revenues on the rollout of the LYMPHIR drug for lymphoma therapy. However, a high burn rate and fierce competition create financial risks, while development is conducted through clinical alliances. GURU.Markets analytics includes this chart, where the company's trading revenue reflects business dynamics, and the 0.01 mark indicates the current sales level.

Citius Oncology Inc. (CTOR) Company Sales: for the period 08/14/2024 - 11/16/2026

Analytical breakdowns for Citius Oncology Inc. (CTOR)

Comprehensive company analysis:Citius Oncology, Inc.
Manufactured product of Citius Oncology

Investors are seeking fundamental supports in the financial statements of Citius Oncology, Inc. (CTOR) to assess business resilience. This indicator captures the actual cash inflow from the sale of products and services. When analyzing the current sales dynamics of Citius Oncology, Inc. (CTOR), it should be noted that a smooth trend line may mask the risk of sharp declines. For biopharmaceuticals, this flow depends directly on the effective implementation of sustainable synthesis methods. Optimizing energy costs in laboratories determines the long-term profitability of operating activities.

Competing companies

Company Revenue ONC|Revenue and Sales Volume HALO|RVMD (Revolution Medicines, Inc.) - Company Sales Revenue|Company Revenue Ascentage Pharma Corp AAPG|Company Total Sales Volume CG Oncology, Inc.|URGN - Company Revenue|Bicara Therapeutics Inc. (BCAX) - Company Sales|Personalis Inc (PSNL) - Company Revenue|ERAS - Company Gross Revenue|DCTH (Delcath Systems Inc) - Revenue and Sales Volume|Company Revenue YMAB|Revenue and Sales Volume AURA|Company Revenue CADL (Candel)|Accuray, Inc. - Company Sales|SELLAS Life Sciences Group Inc. - Company Revenue|ACTU: Company Sales|HURA: Company Revenue|TARA (Protara) - Company Sales|Fate Therapeutics, Inc. - Company Sales Revenue|WHWK (aadibio.com) - Revenue and Sales Volume|TCRX: Company Sales Revenue|Company Revenue Champions Oncology (CSBR)|XBiotech - Company Sales Volume|Company Revenue CEL-SCI CVM|Company Gross Revenue OS Therapies (OSTX)|Radiopharm Theranostics Limited - Revenue and Sales Volume|Company Total Revenue Artiva Biotherapeutics|ANL (adlainortye.com) - Company Sales|Company Sales Veru Pharma|TPST (Tempest Therapeutics Inc) - Revenue and Sales Volume|Xilio Therapeutics, Inc. (XLO) - Company Gross Revenue|Company Revenue Enochian BioSciences (RENB)|MURA: Company Annual Revenue|Revenue and Sales Volume KAPA (kairospharma.com)|Company Gross Revenue OnKure (OKUR)|CytoMed Therapeutics Ltd - Revenue and Sales Volume|curis.com (CRIS) - Company Sales|Apollomics Corp (APLM) - Company Revenue|Tharimmune - Company Sales Revenue|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue